VVM
LENZ

Versant Venture Management’s LENZ Therapeutics LENZ Stock Holding History

Versant Venture Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.3M Hold
2,656,888
– – 17.19% 3
2025
Q4 		$42.5M Hold
2,656,888
– – 28.14% 2
2025
Q3 		$124M Buy
+2,656,888
New +$97.7M 58.25% 1

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Versant Venture Management's LENZ Position: Q1 2026 in Review

Versant Venture Management held its LENZ Therapeutics (LENZ) position steady in Q1 2026 at 2,656,888 shares worth $24.3M. The position accounts for 17.19% of the portfolio, ranked #3.

Versant Venture Management first reported a position in LENZ in Q3 2025 and has held it in 3 quarters since. The position peaked at $124M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Versant Venture Management held 2,656,888 shares of LENZ Therapeutics worth $24.3M as of Q1 2026.
  • Versant Venture Management left its LENZ Therapeutics share count unchanged in Q1 2026.
  • LENZ Therapeutics made up 17.19% of Versant Venture Management's portfolio in Q1 2026, its #3 holding.
  • Versant Venture Management first reported a position in LENZ Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Versant Venture Management's LENZ Therapeutics position peaked at $124M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Versant Venture Management's 13F filing for Q1 2026, filed 5 May 2026.